Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Tanzania

Inclusion Criteria: * Children aged 6-59 months * glucose-6-phosphate dehydrogenase (G6PD) normal (qualitative screen) in sites where P. vivax or P. ovale known prevalence rates represent major burden) and whose treatment with primaquine is implemented within national guidelines * Hb \> 5mg/dl * Temperature ≤38.0°C) and no moderate or severe acute illness/infection on the day of inclusion * Sleeps in cluster \>90% of nights during any given month * No plans for extended travel (\<1month) outside of home during study * Not participating in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial * Provision of assent/informed consent form signed by the subject and by the parent(s) or another legally acceptable representative Exclusion Criteria: * children \< 6 months or \> 5 years * G6PD deficiency (qualitative screen) in sites where P. vivax or P. ovale known prevalence rates represent major burden and whose treatment with primaquine is implemented within national guidelines * Severe anemia * Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection on the day of inclusion * Sleeps in cluster \<90% of nights during any given month * Plans for extended travel (\>1month) outside of home during study * Participating or planned participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure during the trial * No provision of assent/informed consent form …